Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies-Reference-Cited by-同舟云学术

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies

Published:2014-10 Issue:15 Volume:50 Page:2677-2684
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Smolewski Piotr,Robak Pawel,Cebula-Obrzut Barbara,Misiewicz Małgorzata,Mędra Aleksandra,Majchrzak Agata,Witkowska Magdalena,Stromatt Scott,Robak Tadeusz

Funder

Medical University of Lodz, Poland

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies;Robak;Curr Opin Invest Drugs,2009

2. Phase 2 study of otlertuzumab (TRU-016), an anti-cd37 ADAPTIR™ protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL);Robak;Blood,2013

3. Novel agents for the treatment of chronic lymphocytic leukemia;Abou-Nassar;Clin Adv Hematol Oncol,2010

4. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment;Hallek;Am J Hematol,2013

5. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia;Robak;Future Oncol,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies;International Journal of Molecular Sciences;2020-12-15

2. Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies;Expert Opinion on Investigational Drugs;2018-01-15

3. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models;Neoplasia;2017-09

4. Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia;British Journal of Haematology;2016-12-15

5. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia;Expert Opinion on Drug Safety;2016-12-04